GLOBAL BIOENERGIES: Global Bioenergies to present results of engine testing with renewable fuels

                                          Global Bioenergies to present results of engine testing with renewable fuelsEvry (France) -March 22 nd, 2018 - Global Bioenergies (Euronext Growth: ALGBE) will present engine testing results on April 5 th. Its commercial partner Audi, and...
Comunicato Precedente

next
Comunicato Successivo

next

             
             

            Global Bioenergies to present results of engine testing with renewable fuels

Evry (France) -March 22nd, 2018 - Global Bioenergies (Euronext Growth: ALGBE) will present engine testing results on April 5th. Its commercial partner Audi, and German engine & fuels specialist FEV, will join the presentation.

About GLOBAL BIOENERGIES

Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performance of its process, to operate its demo plant in Germany, and to prepare the first full-scale plant through a joint venture with Cristal Union, named IBN-One. Global Bioenergies is listed on Euronext Growth Paris (FR0011052257 - ALGBE).

Stay informed! Subscribe to our newsfeed on
www.global-bioenergies.com

Follow us on Twitter: @GlobalBioenergi

Contact

GLOBAL BIOENERGIES
Luc Mathis
Chief Business Officer
Phone:                 +33 1 64 98 20 50
[email protected]

GLOBAL BIOENERGIES PRESS RELEASE



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: GLOBAL BIOENERGIES via Globenewswire

Per maggiori informazioni

Ufficio Stampa

 Nasdaq GlobeNewswire (Leggi tutti i comunicati)
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti

Allegati
Slide ShowSlide Show
Non disponibili
;